Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372194 | 0.80 | DRD4 (0.50) | DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL6266738 | 0.78 | GRM2 (0.53) | MAOAGRM5MAPK1GRM2 | |
| SCHEMBL6266734 | 0.78 | GRM2 (0.53) | MAOAGRM5MAPK1GRM2 | |
| SCHEMBL9582052 | 0.75 | DRD4 (0.73) | DRD4DRD2DRD3 | |
| SCHEMBL9582407 | 0.75 | DRD4 (0.73) | DRD4DRD2DRD3 | |
| SCHEMBL1317540 | 0.75 | DRD4 (0.73) | DRD4DRD2DRD3 | |
| SCHEMBL2510348 | 0.75 | KDM4E (0.48) | DRD4DRD2DRD3SIGMAR1KDM4E | |
| SCHEMBL17005417 | 0.75 | GBA1 (0.47) | DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL2308053 | 0.75 | KDM4E (0.48) | DRD4DRD2DRD3SIGMAR1KDM4E | |
| SCHEMBL11652625 | 0.73 | MAOA (0.40) | MAOAGRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | DRD4 4086/4885MAOA 618/4885GRM5 4546/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | DRD4 3654/4885MAOA 693/4885GRM5 4484/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | DRD4 3728/4885MAOA 494/4885GRM5 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.